Cargando…

Corrected QT Interval (QTc) Diagnostic App for the Oncological Routine: Development Study

BACKGROUND: Numerous antineoplastic drugs such as chemotherapeutics have cardiotoxic side effects and can lead to long QT syndrome (LQTS). When diagnosed and treated in time, the potentially fatal outcomes of LQTS can be prevented. Therefore, regular electrocardiogram (ECG) assessments are critical...

Descripción completa

Detalles Bibliográficos
Autores principales: Klier, Kristina, Patel, Yash J, Schinköthe, Timo, Harbeck, Nadia, Schmidt, Annette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520775/
https://www.ncbi.nlm.nih.gov/pubmed/37695655
http://dx.doi.org/10.2196/48096
_version_ 1785109996089901056
author Klier, Kristina
Patel, Yash J
Schinköthe, Timo
Harbeck, Nadia
Schmidt, Annette
author_facet Klier, Kristina
Patel, Yash J
Schinköthe, Timo
Harbeck, Nadia
Schmidt, Annette
author_sort Klier, Kristina
collection PubMed
description BACKGROUND: Numerous antineoplastic drugs such as chemotherapeutics have cardiotoxic side effects and can lead to long QT syndrome (LQTS). When diagnosed and treated in time, the potentially fatal outcomes of LQTS can be prevented. Therefore, regular electrocardiogram (ECG) assessments are critical to ensure patient safety. However, these assessments are associated with patient discomfort and require timely support of the attending oncologist by a cardiologist. OBJECTIVE: This study aimed to examine whether this approach can be made more efficient and comfortable by a smartphone app (QTc Tracker), supporting single-lead ECG records on site and transferring to a tele-cardiologist for an immediate diagnosis. METHODS: To evaluate the QTc Tracker, it was implemented in 54 cancer centers in Germany. In total, 266 corrected QT interval (QTc) diagnoses of 122 patients were recorded. Moreover, a questionnaire on routine ECG workflow, turnaround time, and satisfaction (1=best, 6=worst) was answered by the centers before and after the implementation of the QTc Tracker. RESULTS: Compared to the routine ECG workflow, the QTc Tracker enabled a substantial turnaround time reduction of 98% (mean 2.67, 95% CI 1.72-2.67 h) and even further time efficiency in combination with a cardiologic on-call service (mean 12.10, 95% CI 5.67-18.67 min). Additionally, nurses and patients reported higher satisfaction when using the QTc Tracker. In particular, patients’ satisfaction sharply improved from 2.59 (95% CI 2.41-2.88) for the routine ECG workflow to 1.25 (95% CI 0.99-1.51) for the QTc Tracker workflow. CONCLUSIONS: These results reveal a significant improvement regarding reduced turnaround time and increased user satisfaction. Best patient care might be guaranteed as the exposure of patients with an uncontrolled risk of QTc prolongations can be avoided by using the fast and easy QTc Tracker. In particular, as regular side-effect monitoring, the QTc Tracker app promises more convenience for patients and their physicians. Finally, future studies are needed to empirically test the usability and validity of such mobile ECG assessment methods. TRIAL REGISTRATION: ClinicalTrials.gov NCT04055493; https://classic.clinicaltrials.gov/ct2/show/NCT04055493
format Online
Article
Text
id pubmed-10520775
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher JMIR Publications
record_format MEDLINE/PubMed
spelling pubmed-105207752023-09-27 Corrected QT Interval (QTc) Diagnostic App for the Oncological Routine: Development Study Klier, Kristina Patel, Yash J Schinköthe, Timo Harbeck, Nadia Schmidt, Annette JMIR Cardio Original Paper BACKGROUND: Numerous antineoplastic drugs such as chemotherapeutics have cardiotoxic side effects and can lead to long QT syndrome (LQTS). When diagnosed and treated in time, the potentially fatal outcomes of LQTS can be prevented. Therefore, regular electrocardiogram (ECG) assessments are critical to ensure patient safety. However, these assessments are associated with patient discomfort and require timely support of the attending oncologist by a cardiologist. OBJECTIVE: This study aimed to examine whether this approach can be made more efficient and comfortable by a smartphone app (QTc Tracker), supporting single-lead ECG records on site and transferring to a tele-cardiologist for an immediate diagnosis. METHODS: To evaluate the QTc Tracker, it was implemented in 54 cancer centers in Germany. In total, 266 corrected QT interval (QTc) diagnoses of 122 patients were recorded. Moreover, a questionnaire on routine ECG workflow, turnaround time, and satisfaction (1=best, 6=worst) was answered by the centers before and after the implementation of the QTc Tracker. RESULTS: Compared to the routine ECG workflow, the QTc Tracker enabled a substantial turnaround time reduction of 98% (mean 2.67, 95% CI 1.72-2.67 h) and even further time efficiency in combination with a cardiologic on-call service (mean 12.10, 95% CI 5.67-18.67 min). Additionally, nurses and patients reported higher satisfaction when using the QTc Tracker. In particular, patients’ satisfaction sharply improved from 2.59 (95% CI 2.41-2.88) for the routine ECG workflow to 1.25 (95% CI 0.99-1.51) for the QTc Tracker workflow. CONCLUSIONS: These results reveal a significant improvement regarding reduced turnaround time and increased user satisfaction. Best patient care might be guaranteed as the exposure of patients with an uncontrolled risk of QTc prolongations can be avoided by using the fast and easy QTc Tracker. In particular, as regular side-effect monitoring, the QTc Tracker app promises more convenience for patients and their physicians. Finally, future studies are needed to empirically test the usability and validity of such mobile ECG assessment methods. TRIAL REGISTRATION: ClinicalTrials.gov NCT04055493; https://classic.clinicaltrials.gov/ct2/show/NCT04055493 JMIR Publications 2023-09-11 /pmc/articles/PMC10520775/ /pubmed/37695655 http://dx.doi.org/10.2196/48096 Text en ©Kristina Klier, Yash J Patel, Timo Schinköthe, Nadia Harbeck, Annette Schmidt. Originally published in JMIR Cardio (https://cardio.jmir.org), 11.09.2023. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Cardio, is properly cited. The complete bibliographic information, a link to the original publication on https://cardio.jmir.org, as well as this copyright and license information must be included.
spellingShingle Original Paper
Klier, Kristina
Patel, Yash J
Schinköthe, Timo
Harbeck, Nadia
Schmidt, Annette
Corrected QT Interval (QTc) Diagnostic App for the Oncological Routine: Development Study
title Corrected QT Interval (QTc) Diagnostic App for the Oncological Routine: Development Study
title_full Corrected QT Interval (QTc) Diagnostic App for the Oncological Routine: Development Study
title_fullStr Corrected QT Interval (QTc) Diagnostic App for the Oncological Routine: Development Study
title_full_unstemmed Corrected QT Interval (QTc) Diagnostic App for the Oncological Routine: Development Study
title_short Corrected QT Interval (QTc) Diagnostic App for the Oncological Routine: Development Study
title_sort corrected qt interval (qtc) diagnostic app for the oncological routine: development study
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520775/
https://www.ncbi.nlm.nih.gov/pubmed/37695655
http://dx.doi.org/10.2196/48096
work_keys_str_mv AT klierkristina correctedqtintervalqtcdiagnosticappfortheoncologicalroutinedevelopmentstudy
AT patelyashj correctedqtintervalqtcdiagnosticappfortheoncologicalroutinedevelopmentstudy
AT schinkothetimo correctedqtintervalqtcdiagnosticappfortheoncologicalroutinedevelopmentstudy
AT harbecknadia correctedqtintervalqtcdiagnosticappfortheoncologicalroutinedevelopmentstudy
AT schmidtannette correctedqtintervalqtcdiagnosticappfortheoncologicalroutinedevelopmentstudy